Compound News and Research

RSS

TSRI scientists identify compound that shows promise for treating obesity-linked diabetes

Scientists at The Scripps Research Institute (TSRI) have demonstrated a drug-discovery strategy with a double payoff-it enables the rapid selection of chemical compounds that have a desired effect on cells and also highlights how the compounds work.

23 Dec 2013

Key questions to ask about bone marrow transplants

Those who have leukemia, lymphoma or other blood cancer diseases might have heard about bone marrow transplant as a potential treatment. As with any serious procedure, it is important to have all questions answered by a physician before any decision is made.

20 Dec 2013

New antibody could boost strength, muscle mass in patients with cancer and other diseases

A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease, sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology.

20 Dec 2013

MicuRx announces initiation of global clinical development program for MRX-I compound

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the initiation of a global clinical development program for its lead compound MRX-I, a novel oxazolidinone antibiotic for treatment of Gram-positive infections including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.

20 Dec 2013

New research assesses nanomedicine-based approaches for treating cancer

As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.

20 Dec 2013

Researchers discover cancer-killing properties of frankincense in ovarian cancer

Researchers from the University of Leicester have, for the first time, demonstrated the potential of treating ovarian cancer using the Christmas gift frankincense.

20 Dec 2013

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

New surface treatment processes for orthopaedic and dental implants to reduce risk of infection

Researchers at Aalto University have developed a method of selection of new surface treatment processes for orthopaedic and dental implants to reduce the risk of infection.

19 Dec 2013

Study reveals why people are predisposed to cardiovascular disease and death

A genetic trait known to make some people especially sensitive to stress also appears to be responsible for a 38 percent increased risk of heart attack or death in patients with heart disease, scientists at Duke Medicine report.

19 Dec 2013

Researchers discover series of compounds possessing anti-HIV activity

University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.

18 Dec 2013

Mylan obtains exclusive rights from Pfizer to develop, commercialize novel LAMA compound

Mylan Inc. today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist compound for various indications.

18 Dec 2013

Takeda expands commercial platform in Israel

Takeda Pharmaceuticals International GmbH today announced further expansion of its commercial platform with the establishment of its wholly-owned subsidiary in Israel. Together with Algeria, Ecuador, Peru, Singapore and Vietnam, Israel is the sixth sales entity Takeda has opened this year to reinforce its platform in growth markets.

18 Dec 2013

Potential pathway for drug development using photoreactions

For chemists, natural substances are compounds formed by organisms to fulfill the myriad biological functions. This biological activity makes them very interesting for industrial applications, for example as active agents in medication or as plant protection agents.

18 Dec 2013

Professor wins U.S. Patent for use of antioxidant compound used in treatment of obesity

A Skidmore College alumnus and professor have been awarded U.S. Patent No. 8,598,150 for use of an antioxidant compound that shows promise in the treatment of obesity and related disorders, such as type-2 diabetes.

17 Dec 2013

Research findings point to possible new strategy for treating ALS

Amyotrophic lateral sclerosis, better known as Lou Gehrig's disease, is a devastating illness that gradually robs sufferers of muscle strength and eventually causes a lethal, full-body paralysis. The only drug available to treat the disease extends life spans by a meager three months on average.

17 Dec 2013

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.

16 Dec 2013

Artificial sweetener sucralose has biological effects

The artificial sweetener sucralose is a biologically active compound according to an extensive review published by Taylor & Francis in the recent issue of Journal of Toxicology and Environmental Health, Part B: Critical Reviews. "Sucralose, A Synthetic Organochlorine Sweetener: Overview Of Biological Issues" authored by Susan S. Schiffman, PhD, an internationally known sweetener researcher and Kristina I. Rother, MD, MHSc, of the National Institutes of Health (NIH), summarizes the biological properties of sucralose based on hundreds of archival, peer-reviewed scientific journal publications.

13 Dec 2013

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

13 Dec 2013

Researchers discover easy-to-use method for bonding gels and biological tissues

Researchers have discovered an efficient and easy-to-use method for bonding together gels and biological tissues. A team headed by Ludwik Leibler, involving researchers from the Laboratoire Matière Molle et Chimie (CNRS/ESPCI ParisTech) and the Laboratoire Physico-Chimie des Polymères et Milieux Dispersés (CNRS/ UPMC/ESPCI ParisTech), has succeeded in obtaining very strong adhesion between two gels by spreading on their surface a solution containing nanoparticles.

12 Dec 2013

Market research report on global and China insulin industry

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%.

12 Dec 2013

Compound News and Research

TSRI scientists identify compound that shows promise for treating obesity-linked diabetes

Key questions to ask about bone marrow transplants

New antibody could boost strength, muscle mass in patients with cancer and other diseases

MicuRx announces initiation of global clinical development program for MRX-I compound

New research assesses nanomedicine-based approaches for treating cancer

Researchers discover cancer-killing properties of frankincense in ovarian cancer

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

New surface treatment processes for orthopaedic and dental implants to reduce risk of infection

Study reveals why people are predisposed to cardiovascular disease and death

Researchers discover series of compounds possessing anti-HIV activity

Mylan obtains exclusive rights from Pfizer to develop, commercialize novel LAMA compound

Takeda expands commercial platform in Israel

Potential pathway for drug development using photoreactions

Professor wins U.S. Patent for use of antioxidant compound used in treatment of obesity

Research findings point to possible new strategy for treating ALS

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Artificial sweetener sucralose has biological effects

Study: Antisense drugs show activity in wide range of tissues and organs

Researchers discover easy-to-use method for bonding gels and biological tissues

Market research report on global and China insulin industry

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News